Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies?

doi:10.3748/wjg.v23.i15.2640

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 15

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8750)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

619

WORD

258

HTML

4227

Figures (1-3)

148

Tables (1-1)

150

Sum=5402

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

620

Download

705

Sum=1325

Publishing Process of This Article

Item

Count

Browse

893

Download

1130

Sum=2023

Apr 21, 2017 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (19)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Apr 21, 2017; 23(15): 2640-2650
Published online Apr 21, 2017. doi: 10.3748/wjg.v23.i15.2640

Full Size Figure Download Figure

Figure 3 Treatment algorithm for advanced gastroenteropancreatic neuroendocrine tumors. ¹Resection of primary, no (or limited) extrahepatic disease. SSA: Somatostatin analog; IFN: Interferon; PRRT: Peptide receptor radionuclide therapy; TAE: Transarterial embolization; TACE: Transarterial chemoembolization; TARE: Transarterial radioembolization; RFA: Radiofrequency ablation.

Citation: Cavalcoli F, Rausa E, Conte D, Nicolini AF, Massironi S. Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies? World J Gastroenterol 2017; 23(15): 2640-2650
URL: https://www.wjgnet.com/1007-9327/full/v23/i15/2640.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i15.2640